McKESSON REPORTS FISCAL 2027 SECOND QUARTER RESULTS
McKesson Corporation (NYSE:MCK) today announced results for the second quarter ended September 30, 2026.
• Generated $3.1 billion of cash flow from operations and $2.9 billion of Free Cash Flow.
• Raised Adjusted Earnings per Diluted Share guidance range to $45.60 to $46.40, from the previous range of $44.20 to $45.00.
• Fiscal 2027 Adjusted Earnings per Diluted Share guidance range indicates 17% to 19% growth compared to the prior year.
“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise,” said Brian Tyler, chair and chief executive officer. “We continue to invest strategically to advance healthcare outcomes and create long-term value. We further strengthened our portfolio through transactions that will expand our capabilities and deepen our presence in key growth areas, while maintaining our commitment to financial discipline. We are confident in our ability to leverage differentiated solutions and create value for customers, partners, patients, and shareholders. As we close out a strong first half of our fiscal year, I want to thank Team McKesson for their unwavering commitment to excellence and for the impact they make across healthcare every day.”
Second quarter revenues were $111.0 billion, an increase of 8% from a year ago, driven by growth in the North American Pharmaceutical and Oncology & Multispecialty segments due to increased prescription volumes and distribution of specialty products, partially offset by lower contributions from branded pharmaceuticals.
Second quarter earnings per diluted share was $10.44 compared to $8.92 a year ago, an increase of $1.52.
Second quarter Adjusted Earnings per Diluted Share was $11.68 compared to $9.86 a year ago, an increase of 18%, driven by strong operational growth across the North American Pharmaceutical, Oncology & Multispecialty, and Prescription Technology Solutions segments, and a lower share count.
During the three months ended September 30, 2026, McKesson generated cash from operations of $3.1 billion, and invested $123 million in capital expenditures, resulting in Free Cash Flow of $2.9 billion. During the first six months of the fiscal year, McKesson generated cash from operations of $2.9 billion, and invested $275 million in capital expenditures, resulting in Free Cash Flow of $2.6 billion.
For the first six months of the fiscal year, McKesson returned $3.6 billion of cash to shareholders, which included $3.4 billion of common stock repurchases and $198 million of dividend payments.
• McKesson signed an agreement to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
• On October 5, 2026, McKesson signed a definitive agreement to invest approximately $1.4 billion for a minority interest of approximately 49% in Option Care Health, Inc. This transaction aligns with McKesson’s strategy in supporting the delivery of complex specialty therapies and expanding patient access through community-based care. The transaction is subject to customary closing conditions, including approval by Option Care Health’s stockholders and the receipt of required regulatory approvals.
• On November 2, 2026, McKesson completed the acquisition of Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization service. This acquisition represents a meaningful milestone in advancing its strategy in oncology, multispecialty, and biopharma services.
• On November 2, 2026, PRISM Vision Group expanded its network with the addition of Spectrum Vision Partners, adding more than 150 providers and bringing its total provider network to more than 350.
• Revenues were $91.4 billion, an increase of 6%, driven by increased prescription transaction volumes, including higher volumes from specialty products to health systems and strategic accounts, partially offset by lower contributions from branded pharmaceuticals.
• Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit was $1.0 billion, an increase of 22%, driven by growth in the distribution of specialty products to health systems and strategic accounts.
• Revenues were $15.0 billion, an increase of 24%, driven by growth in provider solutions and specialty distribution.
• Segment Operating Profit was $352 million. Adjusted Segment Operating Profit was $427 million, an increase of 8%, driven by growth in provider solutions and specialty distribution.
• Revenues were $1.5 billion, an increase of 10%, driven by increased prescription volumes in third-party logistics and access solutions, partially offset by lower contributions from hub dispensing services.
• Segment Operating Profit was $275 million. Adjusted Segment Operating Profit was $307 million, an increase of 18%, driven by higher demand for access solutions.
• Revenues were $3.1 billion, an increase of 5%, driven by growth across the extended and ambulatory care channels.
• Segment Operating Profit was $164 million. Adjusted Segment Operating Profit was $225 million, a decrease of 10%, driven by lower contributions from the ambulatory care channel due to product mix, partially offset by growth in the extended care channel.
McKesson does not provide forward-looking guidance on a GAAP basis as the company is unable to provide a quantitative reconciliation of forward-looking Non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory- related adjustments, certain litigation loss and gain contingencies, transaction related expenses and adjustments, restructuring, impairment and related charges, and other adjustments, which are difficult to predict and estimate. These items are generally uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.
McKesson is raising its fiscal 2027 Adjusted Earnings per Diluted Share guidance to $45.60 to $46.40 from the previous range of $44.20 to $45.00.
“The raise in fiscal 2027 Adjusted Earnings per Diluted Share guidance is underpinned by the strength in our business and the confidence we have in our ability to execute consistently,” said Kenny Cheung, executive vice president and chief financial officer. “W e are committed to building towards the future through disciplined capital deployment and strategic investments.”
Additional modeling considerations will be provided in the earnings call presentation.
McKesson has scheduled a conference call for today, Wednesday, November 4, 2026, at 4:30 PM ET to discuss the company’s financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website at investor.mckesson.com .
A complete listing of public events open to the investment community will be available on McKesson's Investor Relations website, including details, updates, and a link to each webcast.
GAAP refers to the U.S. generally accepted accounting principles. This press release includes GAAP financial measures as well as Non-GAAP financial measures, including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses, Adjusted Operating Profit, and Free Cash Flow which are financial measures not calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP Financial Information” section of the accompanying financial statement tables for the definitions and usefulness of the company’s Non-GAAP financial measures and the attached schedules for reconciliations of the differences between the Non-GAAP financial measures and their most directly comparable GAAP financial measures.
This earnings release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the negative of these words or other comparable terminology. Any discussion of our intent to separate our Medical-Surgical Solutions segment into an independent company, other anticipated or completed transactions, including the anticipated closings thereof, or synergies expected therefrom, litigation outcomes, financial outlook, guidance, trends, strategy, plans, assumptions, expectations, commitments, and intentions may also include forward-looking statements.
Forward-looking statements are not representations of historical or current facts or circumstances and they involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Readers should not place undue reliance on forward-looking statements, such as financial performance forecasts, which speak only as of the date they are first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events. Although it is not possible to predict or identify all such risks and uncertainties, we encourage investors to read the risk factors described in our publicly available filings with the Securities and Exchange Commission and news releases.
These risk factors include, but are not limited to: our planned separation of Medical-Surgical Solutions and the closing of our investment in Option Care Health, Inc., each of which is subject to conditions, may not be completed on the currently contemplated terms or timeline, or at all, and, if completed, may not achieve the intended financial and strategic benefits; we experience costly and disruptive legal disputes and settlements, including regarding our role in distributing controlled substances such as opioids; we experience losses not covered by insurance or indemnification; we are subject to frequently changing, extensive, complex, and challenging healthcare and other laws and policies; we from time to time record significant charges from impairment to goodwill, intangibles, and other long-lived assets; we experience cybersecurity incidents that might significantly compromise our technology systems or might result in material data breaches; we experience significant problems with information systems or networks; the adoption and use of artificial intelligence in our business operations exposes us to risks and uncertainties; we may be unsuccessful in achieving our strategic growth objectives; we may be unsuccessful in our efforts to implement initiatives to reduce or optimize our costs; we might be unable to successfully complete or integrate acquisitions or other strategic transactions, especially in the timeframes noted; we may not receive anticipated benefits from acquisitions or other strategic transactions; we might be adversely impacted by delays or other difficulties with divestitures; we are impacted by customer purchase reductions, contract non- renewals, payment defaults, and bankruptcies; our contracts with government entities involve future funding, payment, and compliance risks; we might be harmed by changes in our relationships or contracts with suppliers; our use of third-party data is subject to risks and limitations that could impede the growth of our data services business; we might be unable to successfully recruit and retain qualified employees; we might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models; we might be adversely impacted by competition and industry consolidation; we are adversely impacted by changes or disruptions in product supply and have difficulties in sourcing or selling products due to a variety of causes; we are adversely impacted as a result of our distribution of generic pharmaceuticals; we are adversely impacted by changes in the economic environments in which we operate; changes affecting capital and credit markets might impede access to credit, increase borrowing costs, and disrupt banking services for us and our customers and suppliers and might impair the financial soundness of our customers and suppliers; we might be adversely impacted by changes in tax legislation or challenges to our tax positions; and we might be adversely impacted by conditions and events outside of our control, such as widespread public health issues, natural disasters, and geopolitical factors.
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Stories & Insights.
We routinely use our website, investor.mckesson.com , to post information that may be material to investors, such as business developments, earnings, and financial performance, as well as presentation materials and details for upcoming and past events.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
Refer to our applicable filings with the SEC for additional disclosures including our Quarterly Reports on Form 10-Q for fiscal 2027 and 2026 as well as our
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Adjusted Earnings (Non-GAAP) and Adjusted Earnings per Diluted Share (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Adjusted Gross Profit (Non-GAAP), Adjusted Operating Expenses (Non-GAAP), Adjusted Other Income (Non-GAAP), Adjusted Interest Expense (Non-GAAP), and Adjusted Income Tax Expense (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Adjusted Segment Operating Profit (Non- GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non- GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Adjusted Segment Operating Profit (Non- GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non- GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
September 30, 2026 March 31, 2026 ────────────────────────────────────────────────────────────────────────────── ASSETS Current assets Cash and cash equivalents $ 6,528 $ 3,975 Receivables, net 30,806 27,985 Inventories, net 28,217 24,207 Prepaid expenses and other 1,134 1,043 Total current assets 66,685 57,210 Property, plant, and 2,665 2,668 equipment, net Operating lease right-of-use 1,937 2,058 assets Goodwill 11,272 11,316 Intangible assets, net 3,942 4,079 Other non-current assets 5,822 4,992 Total assets $ 92,323 $ 82,323 LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS, AND DEFICIT Current liabilities Drafts and accounts payable $ 67,761 $ 59,973 Current portion of long-term 794 1,267 debt Current portion of operating lease 286 287 liabilities Other accrued liabilities 5,555 5,490 Total current liabilities 74,396 67,017 Long-term debt 8,414 5,259 Long-term deferred tax 1,457 1,330 liabilities Long-term operating lease 1,667 1,801 liabilities Long-term litigation 4,563 5,091 liabilities Other non-current liabilities 2,842 2,659 Redeemable noncontrolling 2,563 943 interests McKesson Corporation stockholders’ deficit Preferred stock, $0.01 par value, 100 shares authorized, no shares — — issued or outstanding Common stock, $0.01 par value, 800 shares authorized, 280 shares 3 3 issued at September 30, 2026 and March 31, 2026 Additional paid-in capital 8,907 8,284 Retained earnings 23,916 22,291 Accumulated other -768 -745 comprehensive loss Treasury shares, at cost, 165 and 160 shares at September 30, 2026 -36,012 -32,005 and March 31, 2026, respectively Total McKesson Corporation stockholders’ -3,954 -2,172 deficit Noncontrolling interests 375 395 Total deficit -3,579 -1,777 Total liabilities, redeemable noncontrolling interests, and $ 92,323 $ 82,323 deficit
Six Months Ended September 30, OPERATING ACTIVITIES 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 2,328 $ 1,994 Adjustments to reconcile to net cash used in operating activities: Depreciation 139 124 Amortization 253 221 Asset impairment 46 4 charges Deferred taxes 18 -41 Credits associated with last-in, -5 -18 first-out inventory method Non-cash operating 152 140 lease expense Gain from sales of businesses and -24 -85 investments Provision for bad debts 83 232 Other non-cash items 145 169 Changes in assets and liabilities: Receivables -2,850 -2,296 Inventories -4,032 -3,199 Drafts and accounts 7,797 5,170 payable Operating lease -148 -152 liabilities Taxes -478 121 Litigation liabilities -529 -657 Other -45 -225 Net cash provided by operating 2,850 1,502 activities INVESTING ACTIVITIES Payments for property, plant, and -177 -217 equipment Capitalized software -98 -168 expenditures Acquisitions, net of cash, cash equivalents, and -23 -3,389 restricted cash acquired Proceeds from sales of businesses and 29 133 investments, net Other -75 53 Net cash used in -344 -3,588 investing activities FINANCING ACTIVITIES Proceeds from — 2,275 short-term borrowings Repayments of — -2,275 short-term borrowings Proceeds from issuances of long-term 3,215 1,990 debt Repayments of long-term -505 -2 debt Common stock transactions: Issuances 56 50 Share repurchases -3,424 -1,399 Dividends paid -198 -179 Sale of noncontrolling interest in 1,238 — Medical-Surgical Solutions, net Other -324 -245 Net cash provided by financing 58 215 activities Effect of exchange rate changes on cash, -13 24 cash equivalents, and restricted cash Net increase (decrease) in cash, cash 2,551 -1,847 equivalents, and restricted cash Cash, cash equivalents, and restricted 4,068 5,956 cash at beginning of period Cash, cash equivalents, and restricted 6,619 4,109 cash at end of period Less: Restricted cash at end of period -91 -105 included in Prepaid expenses and other Cash and cash equivalents at end of $ 6,528 $ 4,004 period
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
For more information relating to the Free Cash Flow (Non-GAAP) definition, refer to the section entitled “Supplemental Non-GAAP Financial Information” of this release.
1) Amounts for the three months ended September 30, 2026 were derived using fiscal 2027 year-to-date Net cash provided by operating activities, Net cash used in investing activities, Net cash provided by (used in) financing activities, Effect of exchange rate changes on cash and cash equivalents, and restricted cash, Payments for property, plant and equipment, and Capitalized software expenditures, less the comparative amounts for the three months ended June 30, 2026 of fiscal 2027. 1 of 1
1. Transaction-related expenses and adjustments for the three months and six months ended September 30, 2026 include pre-tax charges of $46 million ($34 million after-tax) and $114 million ($84 million after-tax), respectively, within Medical-Surgical Solutions and Corporate Expenses, net, related to our planned separation of the Medical-Surgical Solutions business. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
2. Transaction-related expenses and adjustments for the three months and six months ended September 30, 2026 include a credit of $11 million and charge of $282 million, respectively, within Medical-Surgical Solutions, related to the remeasurement to redemption value of redeemable noncontrolling interests arising from the acquisition by Apollo Funds of an approximately 13% minority ownership interest in the Company’s Medical‑Surgical Solutions segment. This charge was recorded in “net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of the accompanying financial statement tables.
3. Transaction-related expenses and adjustments for the three and six months ended September 30, 2026 include a pre-tax and after-tax charge of $28 million and $109 million, respectively, within Oncology & Multispecialty, related to the remeasurement of redeemable noncontrolling interests to redemption value. This charge was recorded in “net income attributable to noncontrolling interests” in the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of the accompanying financial statement tables.
4. Restructuring, impairment, and related charges, net for the three and six months ended September 30, 2026 includes pre-tax charges of $85 million ($63 million after-tax) and $221 million ($163 million after-tax), respectively, primarily within Prescription Technology Solutions, Corporate Expenses, net, and Medical-Surgical Solutions. The three and six months ended September 30, 2025 includes pre-tax charges of $63 million ($46 million after-tax) and $110 million ($81 million after-tax), respectively, primarily within Corporate expenses, net and Medical-Surgical Solutions. These charges are included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables.
5. Other adjustments, net for the six months ended September 30, 2025 includes a pre-tax provision for bad debts of $189 million ($140 million after-tax), within North American Pharmaceutical related to the bankruptcy of our customer, Rite Aid Corporation (including certain of its subsidiaries, "Rite Aid"). Management believes this charge is not reflective of allowances recorded in the normal course of business operations and are related to Rite Aid's recently concluded bankruptcy proceedings, and is therefore excluded from the determination of our adjusted results (Non-GAAP). This charge represents the remaining trade accounts receivable balances due from Rite Aid prior to its bankruptcy petition filing and is included under "total operating expenses" in the reconciliation of McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying financial statement tables. 1 of 3
In an effort to provide investors with additional information regarding the Company's financial results as determined by generally accepted accounting principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents the following Non-GAAP measures in this press release.
Adjusted Gross Profit (Non-GAAP): We define Adjusted Gross Profit as GAAP gross profit, excluding transaction-related expenses and adjustments, last-in, first- out (“LIFO”) inventory-related adjustments, gains from antitrust legal settlements, and other adjustments.
Adjusted Operating Expenses (Non-GAAP): We define Adjusted Operating Expenses as GAAP total operating expenses, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
Adjusted Other Income (Non-GAAP): We define Adjusted Other Income as GAAP other income (expense), net, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, and other adjustments.
Adjusted Interest Expense (Non-GAAP): We define Adjusted Interest Expense as GAAP interest expense, excluding transaction-related expenses and adjustments related to net interest expense incurred from cross-currency swaps used to hedge the changes in the fair value of the Company's foreign currency-denominated notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The foreign currency-denominated notes were previously designated as non-derivative net investment hedges of portions of the Company's net investments in its now-divested European businesses against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar.
Adjusted Income Tax Expense (Non-GAAP): We define Adjusted Income Tax Expense as GAAP income tax benefit (expense), excluding the income tax effects of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments. Income tax effects are calculated in accordance with Accounting Standards Codification ("ASC") 740, “Income Taxes,” which is the same accounting principle used by the Company when presenting its GAAP financial results.
Adjusted Earnings (Non-GAAP): We define Adjusted Earnings as GAAP income attributable to McKesson, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory- related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable.
Adjusted Earnings per Diluted Share (Non-GAAP): We define Adjusted Earnings per Diluted Share as GAAP earnings per diluted common share attributable to McKesson, excluding per share impacts of amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory- related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, other adjustments, as well as the related income tax effects for each of these items, as applicable, divided by diluted weighted-average shares outstanding.
Adjusted Segment Operating Profit (Non-GAAP) and Adjusted Segment Operating Profit Margin (Non-GAAP): We define Adjusted Segment Operating Profit as GAAP segment operating profit, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory- related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, and other adjustments. We define Adjusted Segment Operating Profit Margin as Adjusted Segment Operating Profit (Non-GAAP) divided by GAAP segment revenues.
Adjusted Corporate Expenses (Non-GAAP): We define Adjusted Corporate Expenses as GAAP corporate expenses, net, excluding transaction-related expenses and adjustments, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments. 2 of 3
Adjusted Operating Profit (Non-GAAP): We define Adjusted Operating Profit as GAAP income before interest expense and income taxes, excluding amortization of acquisition-related intangibles, transaction-related expenses and adjustments, LIFO inventory-related adjustments, gains from antitrust legal settlements, restructuring, impairment, and related charges, claims and litigation charges, and other adjustments.
The following provides further details regarding the adjustments made to our GAAP financial results to arrive at our Non-GAAP measures as defined above:
Amortization of acquisition-related intangibles - Amortization charges for intangible assets directly related to business combinations and the formation of joint ventures.
Transaction-related expenses and adjustments - Transaction, integration, and other expenses that are directly related to business combinations, the formation of joint ventures, divestitures, and other transaction-related costs including initial public offering costs. Examples include transaction closing costs, professional service fees, legal fees, severance charges, retention payments and employee relocation expenses, facility or other exit-related expenses, certain fair value adjustments including deferred revenues, contingent consideration and inventory, recoveries of acquisition-related expenses or post-closing expenses, net interest expense impact of hedging foreign currency-denominated notes, bridge loan fees and gains or losses on business combinations, redeemable noncontrolling interests adjustments, and divestitures of businesses that do not qualify as discontinued operations.
LIFO inventory-related adjustments - LIFO inventory-related non-cash charges or credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the Company’s share of antitrust legal settlements.
Restructuring, impairment, and related charges - Restructuring charges that are incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted as well as long-lived asset impairments. Such charges may include employee severance, retention bonuses, facility closure or consolidation costs, lease or contract termination costs, asset impairments, accelerated depreciation and amortization, and other related expenses. The restructuring programs may be implemented due to the sale or discontinuation of a product line, reorganization or management structure changes, headcount rationalization, realignment of operations or products, integration of acquired businesses, and/or company-wide cost saving initiatives. The amount and/or frequency of these restructuring charges are not part of our underlying business, which include normal levels of reinvestment in the business. Any credit adjustments due to subsequent changes in estimates are also excluded from adjusted results.
Claims and litigation charges - Adjustments to certain of the Company’s reserves, including those related to estimated probable settlements for its controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. This does not include our legal fees to defend claims, which are expensed as incurred. This also may include charges or credits for general non-operational claims not directly related to our ongoing business.
Other adjustments - The Company evaluates the nature and significance of transactions qualitatively and quantitatively on an individual basis and may include them in the determination of our adjusted results from time to time. While not all-inclusive, other adjustments may include: other asset impairments; gains or losses from debt extinguishment; and other similar substantive and/or infrequent items as deemed appropriate.
The Company evaluates the aforementioned Non-GAAP measures on a periodic basis and updates the definitions from time to time. The evaluation considers both the quantitative and qualitative aspects of the Company’s presentation of Non-GAAP adjusted results. A reconciliation of McKesson’s GAAP financial results to Non- GAAP financial results is provided in Schedules 2 and 3 of the financial statement tables included with this press release.
Free Cash Flow (Non-GAAP): We define free cash flow as net cash provided by (used in) operating activities less payments for property, plant, and equipment and capitalized software expenditures, as disclosed in our condensed consolidated statements of cash flows. A reconciliation of McKesson’s GAAP financial results to Free Cash Flow (Non-GAAP) is provided in Schedule 6 of the financial statement tables included with this press release. 3 of 3
The Company believes the presentation of Non-GAAP measures provides useful supplemental information to investors with regard to its operating performance, as well as assists with the comparison of its past financial performance to the Company’s future financial results. Moreover, the Company believes that the presentation of Non-GAAP measures assists investors’ ability to compare its financial results to those of other companies in the same industry. However, the Company's Non-GAAP measures used in the press tables may be defined and calculated differently by other companies in the same industry.
The Company internally uses both GAAP and Non-GAAP financial measures in connection with its own financial planning and reporting processes. Management utilizes Non-GAAP financial measures when allocating resources, deploying capital, as well as assessing business performance, and determining employee incentive compensation. The Company conducts its businesses internationally in local currencies, including Canadian dollars, Euro, and British pound sterling. As a result, the comparability of our results reported in U.S. dollars can be affected by changes in foreign currency exchange rates. We believe free cash flow is important to management and useful to investors as a supplemental measure as it indicates the cash flow available for working capital needs, re- investment opportunities, strategic acquisitions, share repurchases, dividend payments, or other strategic uses of cash. Nonetheless, Non-GAAP adjusted results and related Non-GAAP measures disclosed by the Company should not be considered a substitute for, nor superior to, financial results and measures as determined or calculated in accordance with GAAP.
Full text with the tables
Exhibit 99.1
McKESSON REPORTS FISCAL 2027 SECOND QUARTER RESULTS
AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE
IRVING, Texas, November 4, 2026 -
McKesson Corporation (NYSE:MCK) today announced results for the second quarter
ended September 30, 2026.
Second Quarter Highlights:
• Consolidated revenues of $111.0 billion increased 8%.
• Earnings per diluted share of $10.44 increased $1.52.
• Adjusted Earnings per Diluted Share of $11.68 increased 18%.
• Generated $3.1 billion of cash flow from operations and $2.9 billion of Free
Cash Flow.
Fiscal 2027 Full Year Outlook:
• Raised Adjusted Earnings per Diluted Share guidance range to $45.60 to $46.40,
from the previous range of $44.20 to $45.00.
• Fiscal 2027 Adjusted Earnings per Diluted Share guidance range indicates 17%
to 19% growth compared to the prior year.
• The Company does not forecast GAAP earnings per diluted share 1 .
“McKesson delivered another quarter of strong results, reflecting operational
strength in our core business segments and disciplined execution across the
enterprise,” said Brian Tyler, chair and chief executive officer. “We continue
to invest strategically to advance healthcare outcomes and create long-term
value. We further strengthened our portfolio through transactions that will
expand our capabilities and deepen our presence in key growth areas, while
maintaining our commitment to financial discipline. We are confident in our
ability to leverage differentiated solutions and create value for customers,
partners, patients, and shareholders. As we close out a strong first half of our
fiscal year, I want to thank Team McKesson for their unwavering commitment to
excellence and for the impact they make across healthcare every day.”
Fiscal 2027 Second Quarter Result Summary
($
in
m…
e…
p… Se…
s… Qu… % Ye… %
a… FY… FY26 Cha… FY… FY… Ch…
──────────────────────────────────────────────────────────────────────────────
R… $ 11… $ 10… 8 $ 216… $ 200… 8
N…
i…
a… 1,… 1,… 10 1,8… 1,8… -3
to
M…
C…
A… 1,… 1,… 11 2,5… 2,2… 12
E…
E…
p…
d…
c…
s… 10… 8.… 17 15.… 15.… 2
a…
to
M…
C…
A…
E…
p… 11… 9.… 18 21.… 18.… 19
D…
S…
1…
b…
u…
"…
2…
O…
f…
f…
e…
2…
r…
in
t…
e…
r…
a…
n…
f…
m…
r…
to
t…
a…
d…
a…
r…
s…
Second quarter revenues were $111.0 billion, an increase of 8% from a year ago,
driven by growth in the North American Pharmaceutical and Oncology &
Multispecialty segments due to increased prescription volumes and distribution
of specialty products, partially offset by lower contributions from branded
pharmaceuticals.
Second quarter earnings per diluted share was $10.44 compared to $8.92 a year
ago, an increase of $1.52.
Second quarter Adjusted Earnings per Diluted Share was $11.68 compared to $9.86
a year ago, an increase of 18%, driven by strong operational growth across the
North American Pharmaceutical, Oncology & Multispecialty, and Prescription
Technology Solutions segments, and a lower share count.
During the three months ended September 30, 2026, McKesson generated cash from
operations of $3.1 billion, and invested $123 million in capital expenditures,
resulting in Free Cash Flow of $2.9 billion. During the first six months of the
fiscal year, McKesson generated cash from operations of $2.9 billion, and
invested $275 million in capital expenditures, resulting in Free Cash Flow of
$2.6 billion.
For the first six months of the fiscal year, McKesson returned $3.6 billion of
cash to shareholders, which included $3.4 billion of common stock repurchases
and $198 million of dividend payments.
Business Highlights
• McKesson signed an agreement to extend its pharmaceutical distribution
partnership with CVS Health through June 2032.
• On October 5, 2026, McKesson signed a definitive agreement to invest
approximately $1.4 billion for a minority interest of approximately 49% in
Option Care Health, Inc. This transaction aligns with McKesson’s strategy in
supporting the delivery of complex specialty therapies and expanding patient
access through community-based care. The transaction is subject to customary
closing conditions, including approval by Option Care Health’s stockholders and
the receipt of required regulatory approvals.
• On November 2, 2026, McKesson completed the acquisition of Precision Medicine
Group, LLC, a global provider of clinical research and biopharma
commercialization service. This acquisition represents a meaningful milestone in
advancing its strategy in oncology, multispecialty, and biopharma services.
• On November 2, 2026, PRISM Vision Group expanded its network with the addition
of Spectrum Vision Partners, adding more than 150 providers and bringing its
total provider network to more than 350.
North American Pharmaceutical Segment
• Revenues were $91.4 billion, an increase of 6%, driven by increased
prescription transaction volumes, including higher volumes from specialty
products to health systems and strategic accounts, partially offset by lower
contributions from branded pharmaceuticals.
• Segment Operating Profit was $1.1 billion. Adjusted Segment Operating Profit
was $1.0 billion, an increase of 22%, driven by growth in the distribution of
specialty products to health systems and strategic accounts.
Oncology & Multispecialty Segment
• Revenues were $15.0 billion, an increase of 24%, driven by growth in provider
solutions and specialty distribution.
• Segment Operating Profit was $352 million. Adjusted Segment Operating Profit
was $427 million, an increase of 8%, driven by growth in provider solutions and
specialty distribution.
Prescription Technology Solutions Segment
• Revenues were $1.5 billion, an increase of 10%, driven by increased
prescription volumes in third-party logistics and access solutions, partially
offset by lower contributions from hub dispensing services.
• Segment Operating Profit was $275 million. Adjusted Segment Operating Profit
was $307 million, an increase of 18%, driven by higher demand for access
solutions.
Medical-Surgical Solutions Segment
• Revenues were $3.1 billion, an increase of 5%, driven by growth across the
extended and ambulatory care channels.
• Segment Operating Profit was $164 million. Adjusted Segment Operating Profit
was $225 million, a decrease of 10%, driven by lower contributions from the
ambulatory care channel due to product mix, partially offset by growth in the
extended care channel.
Fiscal 2027 Outlook
McKesson does not provide forward-looking guidance on a GAAP basis as the
company is unable to provide a quantitative reconciliation of forward-looking
Non-GAAP measures to the most directly comparable forward-looking GAAP measure,
without unreasonable effort. McKesson cannot reasonably forecast LIFO inventory-
related adjustments, certain litigation loss and gain contingencies, transaction
related expenses and adjustments, restructuring, impairment and related charges,
and other adjustments, which are difficult to predict and estimate. These items
are generally uncertain and depend on various factors, many of which are beyond
the company's control, and as such, any associated estimate and its impact on
GAAP performance could vary materially.
McKesson is raising its fiscal 2027 Adjusted Earnings per Diluted Share guidance
to $45.60 to $46.40 from the previous range of $44.20 to $45.00.
“The raise in fiscal 2027 Adjusted Earnings per Diluted Share guidance is
underpinned by the strength in our business and the confidence we have in our
ability to execute consistently,” said Kenny Cheung, executive vice president
and chief financial officer. “W e are committed to building towards the future
through disciplined capital deployment and strategic investments.”
Additional modeling considerations will be provided in the earnings call
presentation.
Conference Call Details
McKesson has scheduled a conference call for today, Wednesday, November 4, 2026,
at 4:30 PM ET to discuss the company’s financial results. The audio webcast of
the conference call will be available live and archived on McKesson's Investor
Relations website at investor.mckesson.com .
Upcoming Investor Events
McKesson management will participate in the following investor events:
• Jefferies Global Healthcare Conference, November 17, 2026
• Evercore Healthcare Conference, December 1, 2026
• J.P. Morgan Healthcare Conference, January 11-14, 2027
A complete listing of public events open to the investment community will be
available on McKesson's Investor Relations website, including details, updates,
and a link to each webcast.
Non-GAAP Financial Measures
GAAP refers to the U.S. generally accepted accounting principles. This press
release includes GAAP financial measures as well as Non-GAAP financial measures,
including Adjusted Gross Profit, Adjusted Operating Expenses, Adjusted Other
Income, Adjusted Interest Expense, Adjusted Income Tax Expense, Adjusted
Earnings, Adjusted Earnings per Diluted Share, Adjusted Segment Operating
Profit, Adjusted Segment Operating Profit Margin, Adjusted Corporate Expenses,
Adjusted Operating Profit, and Free Cash Flow which are financial measures not
calculated in accordance with GAAP. Refer to the “Supplemental Non-GAAP
Financial Information” section of the accompanying financial statement tables
for the definitions and usefulness of the company’s Non-GAAP financial measures
and the attached schedules for reconciliations of the differences between the
Non-GAAP financial measures and their most directly comparable GAAP financial
measures.
Cautionary Statements
This earnings release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements may be identified by their use
of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,”
“should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,”
“targets,” or the negative of these words or other comparable terminology. Any
discussion of our intent to separate our Medical-Surgical Solutions segment into
an independent company, other anticipated or completed transactions, including
the anticipated closings thereof, or synergies expected therefrom, litigation
outcomes, financial outlook, guidance, trends, strategy, plans, assumptions,
expectations, commitments, and intentions may also include forward-looking
statements.
Forward-looking statements are not representations of historical or current
facts or circumstances and they involve known and unknown risks and
uncertainties that could cause actual results to differ materially from those
projected, anticipated, or implied. Readers should not place undue reliance on
forward-looking statements, such as financial performance forecasts, which speak
only as of the date they are first made. Except to the extent required by
federal securities laws, we undertake no obligation to publicly release the
result of any revisions to any forward-looking statements to reflect events or
circumstances after the date the statements are made, or to reflect the
occurrence of unanticipated events. Although it is not possible to predict or
identify all such risks and uncertainties, we encourage investors to read the
risk factors described in our publicly available filings with the Securities and
Exchange Commission and news releases.
These risk factors include, but are not limited to: our planned separation of
Medical-Surgical Solutions and the closing of our investment in Option Care
Health, Inc., each of which is subject to conditions, may not be completed on
the currently contemplated terms or timeline, or at all, and, if completed, may
not achieve the intended financial and strategic benefits; we experience costly
and disruptive legal disputes and settlements, including regarding our role in
distributing controlled substances such as opioids; we experience losses not
covered by insurance or indemnification; we are subject to frequently changing,
extensive, complex, and challenging healthcare and other laws and policies; we
from time to time record significant charges from impairment to goodwill,
intangibles, and other long-lived assets; we experience cybersecurity incidents
that might significantly compromise our technology systems or might result in
material data breaches; we experience significant problems with information
systems or networks; the adoption and use of artificial intelligence in our
business operations exposes us to risks and uncertainties; we may be
unsuccessful in achieving our strategic growth objectives; we may be
unsuccessful in our efforts to implement initiatives to reduce or optimize our
costs; we might be unable to successfully complete or integrate acquisitions or
other strategic transactions, especially in the timeframes noted; we may not
receive anticipated benefits from acquisitions or other strategic transactions;
we might be adversely impacted by delays or other difficulties with
divestitures; we are impacted by customer purchase reductions, contract non-
renewals, payment defaults, and bankruptcies; our contracts with government
entities involve future funding, payment, and compliance risks; we might be
harmed by changes in our relationships or contracts with suppliers; our use of
third-party data is subject to risks and limitations that could impede the
growth of our data services business; we might be unable to successfully recruit
and retain qualified employees; we might be adversely impacted by healthcare
reform such as changes in pricing and reimbursement models; we might be
adversely impacted by competition and industry consolidation; we are adversely
impacted by changes or disruptions in product supply and have difficulties in
sourcing or selling products due to a variety of causes; we are adversely
impacted as a result of our distribution of generic pharmaceuticals; we are
adversely impacted by changes in the economic environments in which we operate;
changes affecting capital and credit markets might impede access to credit,
increase borrowing costs, and disrupt banking services for us and our customers
and suppliers and might impair the financial soundness of our customers and
suppliers; we might be adversely impacted by changes in tax legislation or
challenges to our tax positions; and we might be adversely impacted by
conditions and events outside of our control, such as widespread public health
issues, natural disasters, and geopolitical factors.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to
advancing health outcomes for patients everywhere. Our teams partner with
biopharma companies, care providers, pharmacies, manufacturers, governments, and
others to deliver insights, products and services to help make quality care more
accessible and affordable. Learn more about how McKesson is impacting virtually
every aspect of healthcare at McKesson.com and read Stories & Insights.
We routinely use our website, investor.mckesson.com , to post information that
may be material to investors, such as business developments, earnings, and
financial performance, as well as presentation materials and details for
upcoming and past events.
Contacts:
Investors
Investors@McKesson.com
Media Relations
MediaRelations@McKesson.com
Schedule 1
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (GAAP)
(unaudited)
(in millions, except per share amounts)
Th… S…
Mo… M…
En… E…
Se… S…
20… 30, 20… Ch… 20… 3… 20… Ch…
──────────────────────────────────────────────────────────────────────────────
R… $ 11… $ 10… 8 % $ 2… $ 2… 8 %
C…
of -1… -9… 7 -… -… 7
s…
G… 3,… 3,… 12 7… 6… 12
p…
S…
d…
g… -2… -2… 9 -… -… 6
a…
a…
e…
C…
a…
l… 2 2 — 36 2 —
c…
n…
R…
i…
a… -85 -63 35 -… -… 1…
r…
c…
n…
T…
o… -2… -2… 10 -… -… 8
e…
O… 1,… 1,… 14 2… 2… 20
i…
O…
i… 63 62 2 1… 1… 2
(…
n…
I… -1… -74 42 -… -… 48
e…
I…
b… 1,… 1,… 12 2… 2… 17
i…
t…
I…
t… -2… -2… 15 -… -… 20
e…
N… 1,… 1,… 11 2… 1… 17
i…
N…
i…
a… -78 -53 47 -… -… 3…
to
n…
i…
N…
i…
a… $ 1,… $ 1,… 10 % $ 1… $ 1… -3 %
to
M…
C…
E…
p…
c…
s…
a…
to
M…
C…
D… $ 10… $ 8.… 17 % $ 1… $ 1… 2 %
B… $ 10… $ 8.… 17 % $ 1… $ 1… 2 %
D…
d…
p… $ 0.… $ 0.… 15 % $ 1… $ 1… 15 %
c…
s…
W…
c…
s…
o…
D… 11… 12… -6 % 1… 1… -6 %
B… 11… 12… -6 1… 1… -6 %
(a) Certain computations may reflect rounding adjustments.
Any percentage changes displayed above which are not meaningful are displayed as
zero percent.
Refer to our applicable filings with the SEC for additional disclosures
including our Quarterly Reports on Form 10-Q for fiscal 2027 and 2026 as well as
our
Annual Report on Form 10-K for fiscal 2026.
Schedule 2
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions, except per share amounts)
Th… Six
Mo… Mo…
En… En…
Se… Se…
20… 30, 20… C… 2… 30, 2… C…
──────────────────────────────────────────────────────────────────────────────
N…
i… $ 1,… $ 1,… 11 % $ 2,… $ 1,… 17 %
(…
N…
i…
a…
to -78 -53 47 -4… -1… 396
n…
i…
(…
N…
i…
a…
to 1,… 1,… 10 1,… 1,… -3
M…
C…
(…
P…
a…
A…
of 71 80 -11 145 130 12
a…
i…
T…
e… 88 34 159 196 120 63
a…
a…
L…
i… -3 -11 -73 -5 -18 -72
a…
G…
f…
a… -50 — — -56 -8 600
l…
s…
R…
i…
a… 85 63 35 221 110 101
r…
c…
n…
C…
a…
l… -2 -2 — -36 -2 —
c…
n…
O…
a… -2 5 -1… -8 166 -1…
n…
I…
t…
e… -45 -41 10 -1… -1… -6
on
p…
a…
N…
i…
a…
to
n…
i…
e…
on 3 -11 127 366 -12 —
p…
a…
a…
r…
n…
i…
a…
(…
A…
E… $ 1,… $ 1,… 11 % $ 2,… $ 2,… 12 %
(…
E…
p…
d…
c…
s… $ 10… $ 8.… 17 % $ 15… $ 15… 2 %
a…
to
M…
C…
(…
A…
a…
A…
of 0.… 0.… -2 0.… 0.… 14
a…
i…
T…
e… 0.… 0.… 224 4.… 0.… 470
a…
a…
L…
i… -0… -0… -71 -0… -0… -73
a…
G…
f…
a… -0… — — -0… -0… 600
l…
s…
R…
i…
a… 0.… 0.… 43 1.… 0.… 109
r…
c…
n…
C…
a…
l… -0… -0… — -0… -0… —
c…
n…
O…
a… -0… 0.… -1… -0… 0.… -1…
n…
A…
E…
p… $ 11… $ 9.… 18 % $ 21… $ 18… 19 %
D…
S…
(…
D…
w…
c… 11… 12… -6 % 11… 12… -6 %
s…
o…
(a) Certain computations may reflect rounding adjustments.
Any percentage changes displayed above which are not meaningful are displayed as
zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Earnings (Non-GAAP) and Adjusted
Earnings per Diluted Share (Non-GAAP) definitions, refer to the section entitled
“Supplemental Non-GAAP Financial Information” of this release.
Schedule 2 (continued)
McKESSON CORPORATION
RECONCILIATION OF GAAP OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
Th… Six
Mo… Mo…
En… En…
Se… Se…
20… 30, 20… C… 2… 30, 2… C…
──────────────────────────────────────────────────────────────────────────────
G…
p… $ 3,… $ 3,… 12 % $ 7,… $ 6,… 12 %
(…
P…
a…
L…
i… -3 -11 -73 -5 -18 -72
a…
G…
f…
a… -50 — — -56 -8 600
l…
s…
O…
a… — 3 -1… — 3 -1…
n…
A…
G… $ 3,… $ 3,… 10 % $ 7,… $ 6,… 12 %
P…
(…
T…
o… $ -2… $ -2… 10 % $ -4… $ -4… 8 %
e…
(…
P…
a…
A…
of 71 80 -11 145 130 12
a…
i…
T…
e… 86 28 207 192 109 76
a…
a…
R…
i…
a… 85 63 35 221 110 101
r…
c…
n…
C…
a…
l… -2 -2 — -36 -2 —
c…
n…
O…
a… -2 2 -2… -8 163 -1…
n…
A…
O… $ -2… $ -1… 8 % $ -4… $ -3… 9 %
E…
(…
I…
e… $ -1… $ -74 42 % $ -1… $ -1… 48 %
(…
P…
a…
T…
e… 2 6 -67 4 11 -64
a…
a…
A…
I… $ -1… $ -68 51 % $ -1… $ -1… 59 %
E…
(…
I…
t… $ -2… $ -2… 15 % $ -5… $ -4… 20 %
e…
(…
T…
a…
A…
of -15 -17 -12 -33 -30 10
a…
i…
T…
e… -22 -8 175 -44 -21 110
a…
a…
L…
i… 1 3 -67 1 5 -80
a…
G…
f…
a… 13 — — 15 2 650
l…
s…
R…
i…
a… -22 -17 29 -58 -29 100
r…
c…
n…
C…
a…
l… — — — 9 — —
c…
n…
O…
a… — -2 -1… 1 -43 102
n…
A…
I…
T… $ -3… $ -2… 14 % $ -6… $ -5… 15 %
E…
(…
Any percentage changes displayed above which are not meaningful are displayed as
zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Gross Profit (Non-GAAP), Adjusted
Operating Expenses (Non-GAAP), Adjusted Other Income (Non-GAAP), Adjusted
Interest Expense (Non-GAAP), and Adjusted Income Tax Expense (Non-GAAP)
definitions, refer to the section entitled “Supplemental Non-GAAP Financial
Information” of this release.
Schedule 3
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
…
…
…
…
…
…
… … … …
… … … …
… … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … $ $ … $ $ % 6
… … …
… … …
… … 5
— … …
$ … $ $ … $ $ % 8
$ … $ $ … $ $ % …
… … 8
… … …
… … …
— … …
… … …
… … …
$ … $ $ … $ $ % …
… % … % … …
… … …
… … …
… … …
— … …
Any percentage changes displayed above which are not meaningful are displayed as
zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-
GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-
GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions,
refer to the section entitled “Supplemental Non-GAAP Financial Information” of
this release.
Schedule 3 (continued)
McKESSON CORPORATION
RECONCILIATION OF GAAP SEGMENT OPERATING RESULTS TO ADJUSTED RESULTS (NON-GAAP)
(unaudited)
(in millions)
…
…
…
…
…
…
… … … …
… … … …
… … … … … …
──────────────────────────────────────────────────────────────────────────────
$ … $ $ … $ $ % 5
… … …
… … …
… … 5
— … …
$ … $ $ … $ $ % 8
$ … $ $ … $ $ % …
… … …
… … …
… … …
— … …
… … …
… … 1
$ … $ $ … $ $ % …
… % … % … …
… … …
… … …
… … …
— … …
Any percentage changes displayed above which are not meaningful are displayed as
zero percent.
Refer to the section entitled "Financial Statement Notes" of this release.
For more information relating to the Adjusted Segment Operating Profit (Non-
GAAP), Adjusted Operating Profit (Non-GAAP), Adjusted Corporate Expenses (Non-
GAAP), and Adjusted Segment Operating Profit Margin (Non-GAAP) definitions,
refer to the section entitled “Supplemental Non-GAAP Financial Information” of
this release.
Schedule 4
McKESSON CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions, except per share amounts)
September 30, 2026 March 31, 2026
──────────────────────────────────────────────────────────────────────────────
ASSETS
Current assets
Cash and cash equivalents $ 6,528 $ 3,975
Receivables, net 30,806 27,985
Inventories, net 28,217 24,207
Prepaid expenses and other 1,134 1,043
Total current assets 66,685 57,210
Property, plant, and 2,665 2,668
equipment, net
Operating lease right-of-use 1,937 2,058
assets
Goodwill 11,272 11,316
Intangible assets, net 3,942 4,079
Other non-current assets 5,822 4,992
Total assets $ 92,323 $ 82,323
LIABILITIES, REDEEMABLE
NONCONTROLLING
INTERESTS, AND DEFICIT
Current liabilities
Drafts and accounts payable $ 67,761 $ 59,973
Current portion of long-term 794 1,267
debt
Current portion of operating
lease 286 287
liabilities
Other accrued liabilities 5,555 5,490
Total current liabilities 74,396 67,017
Long-term debt 8,414 5,259
Long-term deferred tax 1,457 1,330
liabilities
Long-term operating lease 1,667 1,801
liabilities
Long-term litigation 4,563 5,091
liabilities
Other non-current liabilities 2,842 2,659
Redeemable noncontrolling 2,563 943
interests
McKesson Corporation
stockholders’
deficit
Preferred stock, $0.01 par
value, 100
shares authorized, no shares — —
issued or
outstanding
Common stock, $0.01 par value,
800
shares authorized, 280 shares 3 3
issued at
September 30, 2026 and March
31, 2026
Additional paid-in capital 8,907 8,284
Retained earnings 23,916 22,291
Accumulated other -768 -745
comprehensive loss
Treasury shares, at cost, 165
and 160
shares at September 30, 2026 -36,012 -32,005
and March
31, 2026, respectively
Total McKesson Corporation
stockholders’ -3,954 -2,172
deficit
Noncontrolling interests 375 395
Total deficit -3,579 -1,777
Total liabilities, redeemable
noncontrolling interests, and $ 92,323 $ 82,323
deficit
Schedule 5
McKESSON CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
(in millions)
Six Months Ended
September 30,
OPERATING ACTIVITIES 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 2,328 $ 1,994
Adjustments to
reconcile to net cash
used in operating
activities:
Depreciation 139 124
Amortization 253 221
Asset impairment 46 4
charges
Deferred taxes 18 -41
Credits associated with
last-in, -5 -18
first-out inventory
method
Non-cash operating 152 140
lease expense
Gain from sales of
businesses and -24 -85
investments
Provision for bad debts 83 232
Other non-cash items 145 169
Changes in assets and
liabilities:
Receivables -2,850 -2,296
Inventories -4,032 -3,199
Drafts and accounts 7,797 5,170
payable
Operating lease -148 -152
liabilities
Taxes -478 121
Litigation liabilities -529 -657
Other -45 -225
Net cash provided by
operating 2,850 1,502
activities
INVESTING ACTIVITIES
Payments for property,
plant, and -177 -217
equipment
Capitalized software -98 -168
expenditures
Acquisitions, net of
cash, cash
equivalents, and -23 -3,389
restricted cash
acquired
Proceeds from sales of
businesses and 29 133
investments, net
Other -75 53
Net cash used in -344 -3,588
investing activities
FINANCING ACTIVITIES
Proceeds from — 2,275
short-term borrowings
Repayments of — -2,275
short-term borrowings
Proceeds from issuances
of long-term 3,215 1,990
debt
Repayments of long-term -505 -2
debt
Common stock
transactions:
Issuances 56 50
Share repurchases -3,424 -1,399
Dividends paid -198 -179
Sale of noncontrolling
interest in 1,238 —
Medical-Surgical
Solutions, net
Other -324 -245
Net cash provided by
financing 58 215
activities
Effect of exchange rate
changes on cash, -13 24
cash equivalents, and
restricted cash
Net increase (decrease)
in cash, cash 2,551 -1,847
equivalents, and
restricted cash
Cash, cash equivalents,
and restricted 4,068 5,956
cash at beginning of
period
Cash, cash equivalents,
and restricted 6,619 4,109
cash at end of period
Less: Restricted cash
at end of period -91 -105
included in Prepaid
expenses and other
Cash and cash
equivalents at end of $ 6,528 $ 4,004
period
Schedule 6
McKESSON CORPORATION
RECONCILIATION OF GAAP CASH FLOW TO FREE CASH FLOW (NON-GAAP)
(unaudited)
(in millions)
Three Six
Months Months
GAAP Ended Ended
CASH Septe… Septem…
FLOW 30,(1) 30,
CATE… 2026 2026 2025 Change
──────────────────────────────────────────────────────────────────────────────
Net
cash
prov… $ 3,070 $ 2,850 $ 1,502 90 %
by
oper…
acti…
Net
cash
used -130 -344 -3,588 -90
in
inve…
acti…
Net
cash
prov…
by -1,574 58 215 -73
(used
in)
fina…
acti…
Effe…
of
exch…
rate
chan…
on -3 -13 24 -154
cash,
cash
equi…
and
rest…
cash
Net
incr…
(dec…
in
cash, $ 1,363 $ 2,551 $ -1,847 238 %
cash
equi…
and
rest…
cash
FREE
CASH
FLOW
(NON…
Net
cash
prov… $ 3,070 $ 2,850 $ 1,502 90 %
by
oper…
acti…
Paym…
for
prop… -65 -177 -217 -18
plan…
and
equi…
Capi…
soft… -58 -98 -168 -42
expe…
Free
Cash $ 2,947 $ 2,575 $ 1,117 131 %
Flow
(Non…
Any percentage changes displayed above which are not meaningful are displayed as
zero percent.
For more information relating to the Free Cash Flow (Non-GAAP) definition, refer
to the section entitled “Supplemental Non-GAAP Financial Information” of this
release.
1) Amounts for the three months ended September 30, 2026 were derived using
fiscal 2027 year-to-date Net cash provided by operating activities, Net cash
used in investing activities, Net cash provided by (used in) financing
activities, Effect of exchange rate changes on cash and cash equivalents, and
restricted cash, Payments for property, plant and equipment, and Capitalized
software expenditures, less the comparative amounts for the three months ended
June 30, 2026 of fiscal 2027.
1 of 1
McKESSON CORPORATION
FINANCIAL STATEMENT NOTES
1. Transaction-related expenses and adjustments for the three months and six
months ended September 30, 2026 include pre-tax charges of $46 million ($34
million after-tax) and $114 million ($84 million after-tax), respectively,
within Medical-Surgical Solutions and Corporate Expenses, net, related to our
planned separation of the Medical-Surgical Solutions business. These charges are
included under "total operating expenses" in the reconciliation of McKesson's
GAAP operating results to adjusted results (Non-GAAP) provided in Schedule 2 of
the accompanying financial statement tables.
2. Transaction-related expenses and adjustments for the three months and six
months ended September 30, 2026 include a credit of $11 million and charge of
$282 million, respectively, within Medical-Surgical Solutions, related to the
remeasurement to redemption value of redeemable noncontrolling interests arising
from the acquisition by Apollo Funds of an approximately 13% minority ownership
interest in the Company’s Medical‑Surgical Solutions segment. This charge was
recorded in “net income attributable to noncontrolling interests” in the
Condensed Consolidated Statements of Operations (GAAP) provided in Schedule 1 of
the accompanying financial statement tables.
3. Transaction-related expenses and adjustments for the three and six months
ended September 30, 2026 include a pre-tax and after-tax charge of $28 million
and $109 million, respectively, within Oncology & Multispecialty, related to the
remeasurement of redeemable noncontrolling interests to redemption value. This
charge was recorded in “net income attributable to noncontrolling interests” in
the Condensed Consolidated Statements of Operations (GAAP) provided in Schedule
1 of the accompanying financial statement tables.
4. Restructuring, impairment, and related charges, net for the three and six
months ended September 30, 2026 includes pre-tax charges of $85 million ($63
million after-tax) and $221 million ($163 million after-tax), respectively,
primarily within Prescription Technology Solutions, Corporate Expenses, net, and
Medical-Surgical Solutions. The three and six months ended September 30, 2025
includes pre-tax charges of $63 million ($46 million after-tax) and $110 million
($81 million after-tax), respectively, primarily within Corporate expenses, net
and Medical-Surgical Solutions. These charges are included under "total
operating expenses" in the reconciliation of McKesson's GAAP operating results
to adjusted results (Non-GAAP) provided in Schedule 2 of the accompanying
financial statement tables.
5. Other adjustments, net for the six months ended September 30, 2025 includes a
pre-tax provision for bad debts of $189 million ($140 million after-tax), within
North American Pharmaceutical related to the bankruptcy of our customer, Rite
Aid Corporation (including certain of its subsidiaries, "Rite Aid"). Management
believes this charge is not reflective of allowances recorded in the normal
course of business operations and are related to Rite Aid's recently concluded
bankruptcy proceedings, and is therefore excluded from the determination of our
adjusted results (Non-GAAP). This charge represents the remaining trade accounts
receivable balances due from Rite Aid prior to its bankruptcy petition filing
and is included under "total operating expenses" in the reconciliation of
McKesson's GAAP operating results to adjusted results (Non-GAAP) provided in
Schedule 2 of the accompanying financial statement tables.
1 of 3
McKESSON CORPORATION
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION
In an effort to provide investors with additional information regarding the
Company's financial results as determined by generally accepted accounting
principles ("GAAP"), McKesson Corporation (the "Company" or "we") also presents
the following Non-GAAP measures in this press release.
•
Adjusted Gross Profit (Non-GAAP): We define Adjusted Gross Profit as GAAP gross
profit, excluding transaction-related expenses and adjustments, last-in, first-
out (“LIFO”) inventory-related adjustments, gains from antitrust legal
settlements, and other adjustments.
•
Adjusted Operating Expenses (Non-GAAP): We define Adjusted Operating Expenses as
GAAP total operating expenses, excluding amortization of acquisition-related
intangibles, transaction-related expenses and adjustments, restructuring,
impairment, and related charges, claims and litigation charges, and other
adjustments.
•
Adjusted Other Income (Non-GAAP): We define Adjusted Other Income as GAAP other
income (expense), net, excluding amortization of acquisition-related
intangibles, transaction-related expenses and adjustments, and other
adjustments.
•
Adjusted Interest Expense (Non-GAAP): We define Adjusted Interest Expense as
GAAP interest expense, excluding transaction-related expenses and adjustments
related to net interest expense incurred from cross-currency swaps used to hedge
the changes in the fair value of the Company's foreign currency-denominated
notes resulting from changes in benchmark interest rates and foreign currency
exchange rates. The foreign currency-denominated notes were previously
designated as non-derivative net investment hedges of portions of the Company's
net investments in its now-divested European businesses against the effect of
exchange rate fluctuations on the translation of foreign currency balances to
the U.S. dollar.
•
Adjusted Income Tax Expense (Non-GAAP): We define Adjusted Income Tax Expense as
GAAP income tax benefit (expense), excluding the income tax effects of
amortization of acquisition-related intangibles, transaction-related expenses
and adjustments, LIFO inventory-related adjustments, gains from antitrust legal
settlements, restructuring, impairment, and related charges, claims and
litigation charges, and other adjustments. Income tax effects are calculated in
accordance with Accounting Standards Codification ("ASC") 740, “Income Taxes,”
which is the same accounting principle used by the Company when presenting its
GAAP financial results.
•
Adjusted Earnings (Non-GAAP): We define Adjusted Earnings as GAAP income
attributable to McKesson, excluding amortization of acquisition-related
intangibles, transaction-related expenses and adjustments, LIFO inventory-
related adjustments, gains from antitrust legal settlements, restructuring,
impairment, and related charges, claims and litigation charges, other
adjustments, as well as the related income tax effects for each of these items,
as applicable.
•
Adjusted Earnings per Diluted Share (Non-GAAP): We define Adjusted Earnings per
Diluted Share as GAAP earnings per diluted common share attributable to
McKesson, excluding per share impacts of amortization of acquisition-related
intangibles, transaction-related expenses and adjustments, LIFO inventory-
related adjustments, gains from antitrust legal settlements, restructuring,
impairment, and related charges, claims and litigation charges, other
adjustments, as well as the related income tax effects for each of these items,
as applicable, divided by diluted weighted-average shares outstanding.
•
Adjusted Segment Operating Profit (Non-GAAP) and Adjusted Segment Operating
Profit Margin (Non-GAAP): We define Adjusted Segment Operating Profit as GAAP
segment operating profit, excluding amortization of acquisition-related
intangibles, transaction-related expenses and adjustments, LIFO inventory-
related adjustments, gains from antitrust legal settlements, restructuring,
impairment, and related charges, and other adjustments. We define Adjusted
Segment Operating Profit Margin as Adjusted Segment Operating Profit (Non-GAAP)
divided by GAAP segment revenues.
•
Adjusted Corporate Expenses (Non-GAAP): We define Adjusted Corporate Expenses as
GAAP corporate expenses, net, excluding transaction-related expenses and
adjustments, restructuring, impairment, and related charges, claims and
litigation charges, and other adjustments.
2 of 3
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
•
Adjusted Operating Profit (Non-GAAP): We define Adjusted Operating Profit as
GAAP income before interest expense and income taxes, excluding amortization of
acquisition-related intangibles, transaction-related expenses and adjustments,
LIFO inventory-related adjustments, gains from antitrust legal settlements,
restructuring, impairment, and related charges, claims and litigation charges,
and other adjustments.
The following provides further details regarding the adjustments made to our
GAAP financial results to arrive at our Non-GAAP measures as defined above:
Amortization of acquisition-related intangibles - Amortization charges for
intangible assets directly related to business combinations and the formation of
joint ventures.
Transaction-related expenses and adjustments - Transaction, integration, and
other expenses that are directly related to business combinations, the formation
of joint ventures, divestitures, and other transaction-related costs including
initial public offering costs. Examples include transaction closing costs,
professional service fees, legal fees, severance charges, retention payments and
employee relocation expenses, facility or other exit-related expenses, certain
fair value adjustments including deferred revenues, contingent consideration and
inventory, recoveries of acquisition-related expenses or post-closing expenses,
net interest expense impact of hedging foreign currency-denominated notes,
bridge loan fees and gains or losses on business combinations, redeemable
noncontrolling interests adjustments, and divestitures of businesses that do not
qualify as discontinued operations.
LIFO inventory-related adjustments - LIFO inventory-related non-cash charges or
credit adjustments.
Gains from antitrust legal settlements - Net cash proceeds representing the
Company’s share of antitrust legal settlements.
Restructuring, impairment, and related charges - Restructuring charges that are
incurred for programs in which we change our operations, the scope of a business
undertaken by our business units, or the manner in which that business is
conducted as well as long-lived asset impairments. Such charges may include
employee severance, retention bonuses, facility closure or consolidation costs,
lease or contract termination costs, asset impairments, accelerated depreciation
and amortization, and other related expenses. The restructuring programs may be
implemented due to the sale or discontinuation of a product line, reorganization
or management structure changes, headcount rationalization, realignment of
operations or products, integration of acquired businesses, and/or company-wide
cost saving initiatives. The amount and/or frequency of these restructuring
charges are not part of our underlying business, which include normal levels of
reinvestment in the business. Any credit adjustments due to subsequent changes
in estimates are also excluded from adjusted results.
Claims and litigation charges - Adjustments to certain of the Company’s
reserves, including those related to estimated probable settlements for its
controlled substance monitoring and reporting, and opioid-related claims, as
well as any applicable income items or credit adjustments due to subsequent
changes in estimates. This does not include our legal fees to defend claims,
which are expensed as incurred. This also may include charges or credits for
general non-operational claims not directly related to our ongoing business.
Other adjustments - The Company evaluates the nature and significance of
transactions qualitatively and quantitatively on an individual basis and may
include them in the determination of our adjusted results from time to time.
While not all-inclusive, other adjustments may include: other asset impairments;
gains or losses from debt extinguishment; and other similar substantive and/or
infrequent items as deemed appropriate.
The Company evaluates the aforementioned Non-GAAP measures on a periodic basis
and updates the definitions from time to time. The evaluation considers both the
quantitative and qualitative aspects of the Company’s presentation of Non-GAAP
adjusted results. A reconciliation of McKesson’s GAAP financial results to Non-
GAAP financial results is provided in Schedules 2 and 3 of the financial
statement tables included with this press release.
•
Free Cash Flow (Non-GAAP): We define free cash flow as net cash provided by
(used in) operating activities less payments for property, plant, and equipment
and capitalized software expenditures, as disclosed in our condensed
consolidated statements of cash flows. A reconciliation of McKesson’s GAAP
financial results to Free Cash Flow (Non-GAAP) is provided in Schedule 6 of the
financial statement tables included with this press release.
3 of 3
SUPPLEMENTAL NON-GAAP FINANCIAL INFORMATION (continued)
The Company believes the presentation of Non-GAAP measures provides useful
supplemental information to investors with regard to its operating performance,
as well as assists with the comparison of its past financial performance to the
Company’s future financial results. Moreover, the Company believes that the
presentation of Non-GAAP measures assists investors’ ability to compare its
financial results to those of other companies in the same industry. However, the
Company's Non-GAAP measures used in the press tables may be defined and
calculated differently by other companies in the same industry.
The Company internally uses both GAAP and Non-GAAP financial measures in
connection with its own financial planning and reporting processes. Management
utilizes Non-GAAP financial measures when allocating resources, deploying
capital, as well as assessing business performance, and determining employee
incentive compensation. The Company conducts its businesses internationally in
local currencies, including Canadian dollars, Euro, and British pound sterling.
As a result, the comparability of our results reported in U.S. dollars can be
affected by changes in foreign currency exchange rates. We believe free cash
flow is important to management and useful to investors as a supplemental
measure as it indicates the cash flow available for working capital needs, re-
investment opportunities, strategic acquisitions, share repurchases, dividend
payments, or other strategic uses of cash. Nonetheless, Non-GAAP adjusted
results and related Non-GAAP measures disclosed by the Company should not be
considered a substitute for, nor superior to, financial results and measures as
determined or calculated in accordance with GAAP.